Krystal Biotech (KRYS) EVP and general counsel sells 642 shares in planned trade

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Krystal Biotech, Inc. executive vice president and general counsel Thomas John Charles sold 642 shares of common stock in an open-market transaction. The shares were sold at an average price of $302.03 per share on May 26, 2026, and his directly held common stock position reported in this filing is now zero shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 23, 2026, which is scheduled to run through December 31, 2026 unless it terminates earlier under its terms.

Insider Trade Summary 10b5-1

Net Seller: 642 shares ($193,903)

Net Sell 1 txn

Insider Thomas John Charles

Role EVP, General Counsel

Sold 642 shs ($194K)

Type	Security	Shares	Price	Value
Sale	Common Stock	642	$302.03	$194K

Holdings After Transaction: Common Stock — 0 shares (Direct, null)

Footnotes (1)

[object Object]

Key Figures

Shares sold: 642 shares Sale price: $302.03 per share Direct holdings after sale: 0 shares +2 more

5 metrics

Shares sold 642 shares Open-market sale of common stock on May 26, 2026

Sale price $302.03 per share Average sale price for 642 common shares

Direct holdings after sale 0 shares Total common stock directly owned following transaction

10b5-1 plan adoption date February 23, 2026 Date Rule 10b5-1 trading plan was adopted

10b5-1 plan end date December 31, 2026 Scheduled termination date unless earlier under plan terms

Key Terms

Rule 10b5-1 trading plan, open-market sale, Common Stock

3 terms

Rule 10b5-1 trading plan regulatory

"The sales reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Common Stock financial

""security_title": "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 Insider Transactions: What Each Field Means →

05/27/2026 - 05:17 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thomas John Charles

(Last)

(First)

(Middle)

C/O KRYSTAL BIOTECH, INC.

2100 WHARTON STREET, SUITE 701

(Street)

PITTSBURGH

PENNSYLVANIA

15203

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Krystal Biotech, Inc. [ KRYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, General Counsel

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/26/2026		S		642⁽¹⁾	D	$302.03	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The sales reported in this Form 4 were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 23, 2026. The Rule 10b5-1 trading plan will terminate on December 31, 2026, or earlier in accordance with the terms of the Rule 10b5-1 trading plan, including upon completion of the sale of all of the shares of the Company's common stock subject to the Rule 10b5-1 trading plan.

Remarks:

	/s/ John C. Thomas	05/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did KRYS executive Thomas John Charles report?

Thomas John Charles reported selling 642 shares of Krystal Biotech common stock. The open-market sale occurred on May 26, 2026 at an average price of $302.03 per share, fully eliminating the directly held common stock position shown in this Form 4.

At what price were the Krystal Biotech (KRYS) shares sold in this Form 4?

The 642 Krystal Biotech common shares were sold at an average price of $302.03 each. This was an open-market transaction, and the filing notes it was carried out under a pre-arranged Rule 10b5-1 trading plan adopted earlier in 2026.

Does the KRYS Form 4 show any remaining direct holdings for Thomas John Charles?

The Form 4 reports zero shares of Krystal Biotech common stock directly owned following the transaction. The filing only discloses this direct holding figure and does not list any remaining derivative positions for the reporting person in the derivative summary section.

Was the KRYS insider sale by Thomas John Charles under a Rule 10b5-1 plan?

Yes. The filing states the sales were executed under a Rule 10b5-1 trading plan adopted on February 23, 2026. The plan is scheduled to terminate on December 31, 2026, or earlier if all covered shares are sold or other plan conditions are met.

What role does Thomas John Charles hold at Krystal Biotech (KRYS)?

Thomas John Charles is listed as an officer of Krystal Biotech, serving as executive vice president and general counsel. His Form 4 filing reports an open-market sale of 642 shares of the company’s common stock under a pre-arranged Rule 10b5-1 trading plan.